Sebastian Gensior

Sebastian Gensior

Zurich
Blending technical expertise with big-picture vision. Innovation in AI, biotech, and VC, Running Capital for Cures. Connect: https://www.linkedin.com/in/sgensior/
19
Mar
The “Game-Changing” Illusion: How Pharma Spins Mediocre Drugs Into Miracles

The “Game-Changing” Illusion: How Pharma Spins Mediocre Drugs Into Miracles

Every year, the pharma industry rolls out its latest batch of “game-changing,” “best-in-class,” and “first-in-class” therapies, showering them with press
4 min read
18
Mar
Venture Debt: A Deal With the Devil You Know

Venture Debt: A Deal With the Devil You Know

capable of wreaking havoc if overindulged. For biotech founders staring down the barrel of cash burn and trial delays, it
4 min read
17
Mar
The Real-World Impacts of Neglecting Extreme Value Theory (EVT) in Biotech and Pharma

The Real-World Impacts of Neglecting Extreme Value Theory (EVT) in Biotech and Pharma

Focusing on the real-world impacts of neglecting Extreme Value Theory (EVT), particularly in biotechnology and pharmaceuticals, offers a potent narrative.
3 min read
16
Mar
Decoding Kaplan-Meier Survival Analysis: A Critical Examination of Its Use and Misuse in Cancer Trials

Decoding Kaplan-Meier Survival Analysis: A Critical Examination of Its Use and Misuse in Cancer Trials

The biotech world thrives on optimism. Pitch decks brimming with breakthroughs and life-saving treatments are a staple of the industry’
4 min read
15
Mar
The problem with POPT

The problem with POPT

The Problem with Probability of Phase Transition (POPT) in Biotech and Pharma Probability of Phase Transition (POPT) is a commonly
4 min read
14
Mar
Case Studies: Failures Due to Ignoring Fat Tails in Biotech Investments

Case Studies: Failures Due to Ignoring Fat Tails in Biotech Investments

Biotech investments are uniquely characterized by uncertainty, where extreme events—whether unexpected breakthroughs or catastrophic failures—play an outsized role.
3 min read
13
Mar
The Great Innovation Theater: Why (Most) Corporate Accelerators Are Just PR on a Budget

The Great Innovation Theater: Why (Most) Corporate Accelerators Are Just PR on a Budget

Every year, large corporations—especially in pharma and biotech—proudly announce new startup accelerators, innovation challenges, or early-stage grant programs
3 min read
12
Mar
Unveiling the Limitations of Survival Analysis: A Closer Look at Hazard Ratios, Cumulative Incidence, and RMST

Unveiling the Limitations of Survival Analysis: A Closer Look at Hazard Ratios, Cumulative Incidence, and RMST

Hazard ratios (HRs) are a widely used measure in survival analysis, summarizing the relative risk of an event occurring in
3 min read
11
Mar
The Lexicon of Uncertainty: Navigating Drug Development’s Risk Metrics

The Lexicon of Uncertainty: Navigating Drug Development’s Risk Metrics

In drug development, where uncertainty reigns supreme and success often feels as elusive as a pot of gold at the
3 min read
10
Mar
Royalty Financing: A Lifeline or a Golden Cage?

Royalty Financing: A Lifeline or a Golden Cage?

Amongst biotech funding options, royalty financing sits as the misunderstood sibling: alluring but mysterious, promising much yet carrying hidden risks.
3 min read